Warren Cresswell Named CEO of Precision Health Firm Perspectum

Cresswell brings over 25 years of experience spanning diagnostics, pharmaceuticals, and medical devices. His background includes building commercial infrastructure for FDA-cleared diagnostics and leading precision oncology firms. At Perspectum, he will oversee the company's efforts to advance non-invasive imaging solutions for liver and cardiometabolic diseases, a sector where the company aims to accelerate drug development and improve patient outcomes.

Leslie Loveless, CEO of Slone Partners, highlighted Cresswell’s track record in scaling organizations as a key asset for Perspectum’s technological expansion. Dr. Michael Rosenblatt, Chairperson of the Perspectum board, echoed this sentiment, noting that the board selected Cresswell specifically for his ability to translate scientific innovation into clinical impact. Cresswell holds a BA in Chemistry from California State University and an MBA from the University of Pittsburgh.